CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


Last Updated: May 9, 2013
Result type: Reports
Project Number: SR0329-000
Product Line: Reimbursement Review

Generic Name: Saxagliptin

Brand Name: Onglyza

Manufacturer: Bristol-Myers Squibb / AstraZeneca Canada Inc.

Therapeutic Area: Diabetes mellitus, type 2

Indications: Diabetes mellitus (Type 2)

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: November 15, 2013

Recommendation Type: List with criteria/condition